330 related articles for article (PubMed ID: 21829009)
1. Association of mean weekly epoetin alfa dose with mortality risk in a retrospective cohort study of Medicare hemodialysis patients.
Weinhandl ED; Gilbertson DT; Collins AJ
Am J Nephrol; 2011; 34(4):298-308. PubMed ID: 21829009
[TBL] [Abstract][Full Text] [Related]
2. Effect of facility-level hemoglobin concentration on dialysis patient risk of transfusion.
Collins AJ; Monda KL; Molony JT; Li S; Gilbertson DT; Bradbury BD
Am J Kidney Dis; 2014 Jun; 63(6):997-1006. PubMed ID: 24315770
[TBL] [Abstract][Full Text] [Related]
3. A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit.
Brophy GM; Sheehan V; Shapiro MJ; Lottenberg L; Scarlata D; Audhya P;
Clin Ther; 2008 Dec; 30(12):2324-34. PubMed ID: 19167591
[TBL] [Abstract][Full Text] [Related]
4. Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization.
Servilla KS; Singh AK; Hunt WC; Harford AM; Miskulin D; Meyer KB; Bedrick EJ; Rohrscheib MR; Tzamaloukas AH; Johnson HK; Zager PG
Am J Kidney Dis; 2009 Sep; 54(3):498-510. PubMed ID: 19628315
[TBL] [Abstract][Full Text] [Related]
5. Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL.
Bradbury BD; Do TP; Winkelmayer WC; Critchlow CW; Brookhart MA
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):932-40. PubMed ID: 19572312
[TBL] [Abstract][Full Text] [Related]
6. Dosing intervals and hemoglobin control in patients with chronic kidney disease and anemia treated with epoetin alfa or darbepoetin alfa: a retrospective cohort study.
Nurko S; Spirko R; Law A; Dennis VW
Clin Ther; 2007 Sep; 29(9):2010-21. PubMed ID: 18035200
[TBL] [Abstract][Full Text] [Related]
7. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
8. Exploring relative mortality and epoetin alfa dose among hemodialysis patients.
Bradbury BD; Wang O; Critchlow CW; Rothman KJ; Heagerty P; Keen M; Acquavella JF
Am J Kidney Dis; 2008 Jan; 51(1):62-70. PubMed ID: 18155534
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients.
Locatelli F; Villa G; Messa P; Filippini A; Cannella G; De Ferrari G; Naso A; Rossi E; Formica M; Lombardi L; Rotolo U; Conte F
J Nephrol; 2008; 21(3):412-20. PubMed ID: 18587731
[TBL] [Abstract][Full Text] [Related]
10. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients.
Regidor DL; Kopple JD; Kovesdy CP; Kilpatrick RD; McAllister CJ; Aronovitz J; Greenland S; Kalantar-Zadeh K
J Am Soc Nephrol; 2006 Apr; 17(4):1181-91. PubMed ID: 16565261
[TBL] [Abstract][Full Text] [Related]
11. Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients.
Bradbury BD; Critchlow CW; Weir MR; Stewart R; Krishnan M; Hakim RH
Nephrol Dial Transplant; 2009 Mar; 24(3):919-25. PubMed ID: 18840893
[TBL] [Abstract][Full Text] [Related]
12. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
[TBL] [Abstract][Full Text] [Related]
13. Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa.
Hymes J; Bickimer T; Jackson JH; Bookhart BK; Mody SH; Tak Piech C
Curr Med Res Opin; 2007 Aug; 23(8):1931-7. PubMed ID: 17624232
[TBL] [Abstract][Full Text] [Related]
14. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes.
Collins AJ; Brenner RM; Ofman JJ; Chi EM; Stuccio-White N; Krishnan M; Solid C; Ofsthun NJ; Lazarus JM
Am J Kidney Dis; 2005 Sep; 46(3):481-8. PubMed ID: 16129210
[TBL] [Abstract][Full Text] [Related]
15. Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis.
St Peter WL; Li S; Liu J; Gilbertson DT; Arneson TJ; Collins AJ
Pharmacotherapy; 2009 Feb; 29(2):154-64. PubMed ID: 19170585
[TBL] [Abstract][Full Text] [Related]
16. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan.
Fukuma S; Yamaguchi T; Hashimoto S; Nakai S; Iseki K; Tsubakihara Y; Fukuhara S
Am J Kidney Dis; 2012 Jan; 59(1):108-16. PubMed ID: 21890255
[TBL] [Abstract][Full Text] [Related]
17. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
19. Effects of Epoetin Alfa Titration Practices, Implemented After Changes to Product Labeling, on Hemoglobin Levels, Transfusion Use, and Hospitalization Rates.
Molony JT; Monda KL; Li S; Beaubrun AC; Gilbertson DT; Bradbury BD; Collins AJ
Am J Kidney Dis; 2016 Aug; 68(2):266-276. PubMed ID: 26980607
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia.
Krivoshiev S; Wizemann V; Czekalski S; Schiller A; Pljesa S; Wolf-Pflugmann M; Siebert-Weigel M; Koytchev R; Bronn A;
Adv Ther; 2010 Feb; 27(2):105-17. PubMed ID: 20369312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
